SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-223135
Filing Date
2018-07-23
Accepted
2018-07-23 07:39:07
Documents
6
Period of Report
2018-07-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d558276d8k.htm 8-K 38357
2 EX-4.1 d558276dex41.htm EX-4.1 71970
3 EX-4.2 d558276dex42.htm EX-4.2 87993
4 EX-10.1 d558276dex101.htm EX-10.1 625307
5 EX-10.2 d558276dex102.htm EX-10.2 200414
6 EX-99.1 d558276dex991.htm EX-99.1 15503
  Complete submission text file 0001193125-18-223135.txt   1041026
Mailing Address 7020 KIT CREEK ROAD SUITE 270 RESEARCH TRIANGLE PARK NC 27709
Business Address 7020 KIT CREEK ROAD SUITE 270 RESEARCH TRIANGLE PARK NC 27709 919-313-9650
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 18963604
SIC: 2836 Biological Products, (No Diagnostic Substances)